Veracyte, Inc. (VCYT)
Nasdaq · Healthcare · Diagnostics & Research
$47.67+4.06%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.8B
- P/E (trailing)
- 34.0
- Forward P/E
- 24.4
- 52-week range
- $29.46 – $60.91
- 52-week change
- +27.11%
- EPS (trailing)
- $1.40
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $517M (+16.01%)
- Net income
- $66.4M
- Operating margin
- 11.2%
- Diluted EPS
- $0.82
- Free cash flow
- $127M
From the company’s annual report on SEC EDGAR.
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Headquarters: South San Francisco, United States · 755 employees · veracyte.com